Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-03-12

Clinical Trial Update: Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ixabepilone in metastatic breast cancer selected by the ixabepilone DRP was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ixabepilone (Ixempra) (ixabepilone)

Snippet

Sponsor: Allarity Therapeutics | Conditions: Metastatic Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2026-03-12